Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Monopar Therapeutics
Report date December 09, 2024 · Filed December 17, 2024
Section 16 reporting ended · disclosed 2024-12-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-12-09 transaction · row 1
1 source rowRow 1 · 2024-12-09 · Other · Disposed 1,433,334 · Balance 0 F1: Tactic Gem, LLC distributed 611,079 shares to Gem Pharmaceuticals, LLC and 822,255 shares to Tactic Pharma, LLC for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Tactic Gem, LLC distributed 611,079 shares to Gem Pharmaceuticals, LLC and 822,255 shares to Tactic Pharma, LLC for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 09, 2024 Filed Dec 17, 2024 16:57 UTC | Monopar Therapeutics MNPR · Entity 5152 | OtherCommon Stock | 1,433,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-037744 · rdgdoc.xml · nonDerivative · entry 1 TacticGem LLC · CIK 0001727358 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Tactic Gem, LLC distributed 611,079 shares to Gem Pharmaceuticals, LLC and 822,255 shares to Tactic Pharma, LLC for no consideration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.